Improvement of osteoblast adhesion, viability, and mineralization by restoring the cell cytoskeleton after bisphosphonate discontinuation in vitro
DOI:
https://doi.org/10.1590/1678-7757-2024-0034Keywords:
Discontinuation, Bisphosphonate, OsteoblastAbstract
Bisphosphonates are prescribed to treat excessive bone resorption in patients with osteoporosis. However, its use is associated with potential adverse effects such as medication-related osteonecrosis of the jaw, prompting the introduction of the drug holiday concept in patients prior to dentoalveolar surgery. Furthermore, bisphosphonate discontinuation has been studied in vivo, in humans, and in animal models. However, it is not known whether this approach could affect bone cells in vitro. Therefore, the objective of this study was to investigate the potential effects of bisphosphonate discontinuation on pre-osteoblast and osteoblast activities in vitro. Methodology: Pre-osteoblasts (MC3T3) and osteoblasts were treated with bisphosphonate (alendronate) at concentrations of 1, 5, and 10 µM. Alendronate was then withdrawn at different time points. The negative control consisted of untreated cells (0 µM), while the positive control consisted of cells incubated with alendronate throughout the experiment. Cell viability, cell adhesion, cell cytoskeleton, mineralization, and gene expressions were investigated. Results: Pre-osteoblasts and osteoblasts showed a decrease in cell viability after treatment with 5-10 μM alendronate for 4 days or longer. Two days of alendronate discontinuation significantly increased cell viability compared with the positive control. However, these levels did not reach those of the negative control. Bone nodule formation was reduced by alendronate. Discontinuation of alendronate regained bone nodule formation. Longer periods of discontinuation were more effective in restoring nodule formation than shorter periods. Addition of alendronate resulted in an increase in the percentage of dead cells, which, in turn, decreased when alendronate was discontinued. Alendronate affected the cell cytoskeleton by disassembling actin stress fibers. Cell adhesion and cell morphological parameters were also affected by alendronate. Discontinuation of alendronate restored cell adhesion and these parameters. Overall, the highest improvement after alendronate discontinuation was seen at 10 µM. However, alendronate treatment and discontinuation did not affect osteoblast gene expression. Conclusion: Discontinuation of alendronate helps to reverse the negative effects of the drug on cell viability, cell adhesion, and mineralization by restoring the cell cytoskeleton. Our data suggest the benefits of drug holiday and/or intermittent strategies for alendronate administration at the cellular level.
Downloads
References
Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013;57:423-8. doi: 10.1016/j.bone.2013.09.008
Tu KN, Lie JD, Wan CK, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: a review of treatment options. PT. 2018;43:92-104
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7. doi: S0278239103007201
Somford MP, Draijer FW, Thomassen, BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736-40. doi: 10.1359/jbmr.090408
Chien HI, Chen LW, Liu WC, Lin CT, Ho YY, Tsai WH, et al. Bisphosphonate-related osteonecrosis of the jaw. Ann Plast Surg. 2021;86:S78-s83. doi: 10.1097/sap.0000000000002650
Kim KK, Park YW, Kim TH, Seo KD. Atypical femoral neck fracture after prolonged bisphosphonate therapy. J Pathol Transl Med. 2020;54:346-50. doi: 10.4132/jptm.2020.05.14
Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360:53-62. doi: 10.1056/NEJMoa0802633
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-301. doi: jc.2004-0952 [pii]10.1210/jc.2004-0952
Marx RE, Tursun, R. Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. Int J Oral Maxillofac Surg. 2012;41:283-9. doi: 10.1016/j.ijom.2011.12.016
Patntirapong S, Korjai N, Matchimapiro M, Sungkaruk P, Suthamporn Y. Geranylgeraniol reverses alendronate-induced MC3T3 cell cytotoxicity and alteration of osteoblast function via cell cytoskeletal maintenance. J Oral Pathol Med. 2021;50:191-9. doi: 10.1111/jop.13120
Atntirapong S, Singhatanadgit W, Arphavasin S. Alendronate-induced atypical bone fracture: evidence that the drug inhibitsosteogenesis. J Clin Pharm Ther. 2014;39:349-53. doi: 10.1111/jcpt.12149
Patntirapong S, Chanruangvanit C, Lavanrattanakul K, Satravaha Y. Assessment of bisphosphonate treated-osteoblast behaviors by conventional assays and a simple digital image analysis. Acta Histochem. 2021;123:151659. doi: 10.1016/j.acthis.2020.151659
Lilakhunakon C, Suwanpateeb J, Patntirapong S. Inhibitory Effects of alendronate on adhesion and viability of preosteoblast cells on titanium discs. Eur J Dent. 2021;15:502-8. doi: 10.1055/s-0041-1726170
Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2016;31:16-35. doi: 10.1002/jbmr.2708
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72:1938-56. doi: 10.1016/j.joms.2014.04.031
Adami G, Jaleel A, Curtis JR, Delzell E, Chen R, Yun H, et al. Temporal trends and factors associated with bisphosphonate discontinuation and restart. J Bone Miner Res. 2020;35:478-87. doi: 10.1002/jbmr.3915
Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, et al. Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J Bone Miner Res. 2018;33:1252-9. doi: 10.1002/jbmr.3420
Ko FC, Karim L, Brooks DJ, Bouxsein ML, Demay MB. Bisphosphonate withdrawal: effects on bone formation and bone resorption in maturing male mice. J Bone Miner Res. 2017;32:814-20. doi: 10.1002/jbmr.3052
Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NF, McCloskey EV, et al. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int. 2018;29:1407-17. doi: 10.1007/s00198-018-4460-6
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-8. doi: 10.1006/meth.2001.1262S1046-2023(01)91262-9
Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49:2-19. doi: 10.1016/j.bone.2011.04.022
Kozloff KM, Volakis LI, Marini JC, Caird, M. S. Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res. 2010;25:1748-58. doi:10.1002/jbmr.66
Patntirapong S, Phupunporn P, Vanichtantiphong D, Thanetchaloempong W. Inhibition of macrophage viability by bound and free bisphosphonates. Acta Histochem. 2019;121:400-6. doi: 10.1016/j.acthis.2019.02.007
Migliorati CA, Saunders D, Conlon MS, Ingstad HK, Vaagen P, Palazzolo MJ, et al. Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction. J Am Dent Assoc. 2013;144:406-14. doi: 10.14219/jada.archive.2013.0134
Shudo A, Kishimoto H, Takaoka K, Noguchi K. Long-term oral bisphosphonates delay healing after tooth extraction: a single institutional prospective study. Osteoporos Int. 2018;29:2315-21. doi: 10.1007/s00198-018-4621-7
Zandi M, Dehghan A, Ghadermazi K, Malekzadeh H, Akbarzadeh M. Perioperative discontinuation of intravenous bisphosphonate therapy reduces the incidence and severity of bisphosphonate-related osteonecrosis of the jaw: a randomized, controlled, prospective experimental study in rats. J Craniomaxillofac Surg. 2015;43:1823-8. doi: https://doi.org/10.1016/j.jcms.2015.08.008
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 Update. J Oral Maxillofac Surg. 2022;80:920-43. doi: 10.1016/j.joms.2022.02.008
Mustakim KR, Eo MY, Oh JH, Lee JY, Myoung H, Kim SM. Significance of medication discontinuation on bisphosphonate-related jaw osteonecrosis in a rat model. Sci Rep. 2022;12:21449. doi: 10.1038/s41598-022-25347-3
Kazmers NH, Ma SA, Yoshida T, Stern PH. Rho GTPase signaling and PTH 3-34, but not PTH 1-34, maintain the actin cytoskeleton and antagonize bisphosphonate effects in mouse osteoblastic MC3T3-E1 cells. Bone. 2009;45:52-60. doi: 10.1016/j.bone.2009.03.675
Chen L, Shi K, Frary CE, Ditzel N, Hu H, Qiu, W, et al. Inhibiting actin depolymerization enhances osteoblast differentiation and bone formation in human stromal stem cells. Stem Cell Res. 2015;15:281-9. doi: 10.1016/j.scr.2015.06.009
Pasqualato A, Lei V, Cucina A, Dinicola S, D’Anselmi F, Proietti S, et al. Shape in migration: quantitative image analysis of migrating chemoresistant HCT-8 colon cancer cells. Cell Adh Migr. 2013;7:450-9. doi: 10.4161/cam.26765
Hong D, Chen HX, Yu HQ, Liang Y, Wang C, Lian QQ, et al. Morphological and proteomic analysis of early stage of osteoblast differentiation in osteoblastic progenitor cells. Exp Cell Res. 2010;316:2291-300. doi: 10.1016/j.yexcr.2010.05.011
Drabek K, van de Peppel J, Eijken M, van Leeuwen JP. GPM6B regulates osteoblast function and induction of mineralization by controlling cytoskeleton and matrix vesicle release. J Bone Miner Res. 2011;26:2045-51. doi: 10.1002/jbmr.435
Vieira AE, Repeke CE, Ferreira SB Jr, Colavite PM, Biguetti CC, Oliveira RC, et al. Intramembranous bone healing process subsequent to tooth extraction in mice: micro-computed tomography, histomorphometric and molecular characterization. PLoS One. 2015;10:e0128021. doi: 10.1371/journal.pone.0128021
Mungpayabarn H, Patntirapong S. Timing of geranylgeraniol addition increases osteoblast activities under alendronate condition. J Oral Biol Craniofac Res. 2021;11:396-401. doi: 10.1016/j.jobcr.2021.04.005
Patntirapong S. Duration and timing of bisphosphonate treatment as factors determining osteoblast mineralization. J Oral Biol Craniofac Res. 2022;12:575-9. doi: 10.1016/j.jobcr.2022.07.011
Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007;356:1075-6. doi: 10.1056/NEJMc062792
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Applied Oral Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
Todo o conteúdo do periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons do tipo atribuição CC-BY.
